Combination of chemotherapy and adoptive immunotherapy with herceptin for patients with HER2-overexpressing breast cancer

Makoto Kubo, Takashi Morisaki, Mitsuo Katano

Research output: Contribution to journalArticlepeer-review

Abstract

We focused on antibody-dependent cellular cytotoxicity (ADCC), one of the efficacy in vivo of Herceptin (trastuzumab) which is a humanized monoclonal antibody against HER2, for patients with HER2-overexpressing breast cancer. As a result, it seems likely that antibody-dependent cellular cytotoxicity (ADCC) plays an important role in the Herceptin-dependent cytotoxicity. Also, it is revealed that taxanes enhances cytotoxicity of natural killer cells, as a immune lymphocytes, due to inducing both perforin and granzyme B expressions. Taken together, these findings suggest that the combination of chemotherapy and Herceptin with various types of activated lymphocytes may be a resonable therapeutic strategy for HER2-overexpressing recurrent breast cancer, inducing effectively ADCC.

Original languageEnglish
Pages (from-to)424-429
Number of pages6
JournalBiotherapy
Volume19
Issue number5
Publication statusPublished - 2005
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combination of chemotherapy and adoptive immunotherapy with herceptin for patients with HER2-overexpressing breast cancer'. Together they form a unique fingerprint.

Cite this